Trial · NCT07541833
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in either resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradient whichever used to judge the initiation of mavacamten treatment | Baseline and up to week 16 | |
| Secondary | Change in Left Ventricular Outflow Tract (LVOT) peak gradient (resting and Valsalva maneuver) | Baseline and up to week 16 | |
| Secondary | Proportion of patients achieving target Left Ventricular Outflow Tract (LVOT) peak gradients (<50 mmHg / <30 mmHg) (Valsalva maneuver or post-exercise) | Baseline and up to week 16 | |
| Secondary | Proportion of patients with any decrease in resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradients | Baseline and up to week 16 | |
| Secondary | Proportion of patients with ≥1 New York Heart Association (NYHA) functional class improvement | Baseline and up to week 16 | |
| Secondary | Change in cardiac biomarkers from baseline | Baseline and up to week 16 | Biomarkers include brain natriuretic peptide (BNP) or N-terminal prohormone of BNP (NT-proBNP) |
| Secondary | Change in systolic function parameters (left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Number of participants with Left Ventricular Ejection Fraction (LVEF) <50% as assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in left ventricular cardiac output (LVCO) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in early diastolic mitral annular velocity (e') measured at the lateral, septal, and averaged positions from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in E/e' ratio measured at the lateral, septal, and averaged positions and E/A ratio (ratio of early (E) to late (A) ventricular filling velocities) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in cardiac structural dimensions from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | Structural dimensions include: septal thickness, posterior wall thickness, maximal left ventricular wall thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and left atrial dimension |
| Secondary | Change in left ventricular outflow tract (LVOT) gradient measured at rest and during Valsalva maneuver from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in cardiac chamber volumes (left ventricular end-diastolic volume, left ventricular end-systolic volume, and left atrial volume) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in indexed cardiac chamber volumes (left ventricular end-diastolic volume index, left ventricular end-systolic volume index, and left atrial volume index) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in left ventricular diameters (left ventricular end-diastolic diameter and left ventricular end-systolic diameter) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in indexed left ventricular diameters (left ventricular end-diastolic diameter index and left ventricular end-systolic diameter index) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in left atrial dimension from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in left ventricular mass index (LVMI) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Number of participants with systolic anterior motion (SAM) of the mitral valve, and number of participants with mitral regurgitation (MR) assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07541833/registered